Wang T, Jacoby MA, Duncavage EJ, Miller CA, Heath S, Rahme R, Fenaux P, Ades L, Renneville A, Cassinat B, et al. Exome analysis of treatment-related AML after APL suggests secondary evolution. Br J Haematol. 2019. 185. 5. 984-987
Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, et al. Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm. Nat Commun. 2019. 10. 1. 1653
Analysis of genomic predispositions to sporadic Myeloid neoplasms mediated by DDX41 in Japan.
(60th ASH Annual Meeting and Exposition 2018)
Lineage-specific RUNX2 super-enhancer activates MYC via translocation (6;8) to promote the development of blastic plasmacytoid dendritic cell neoplasm.
(60th ASH Annual Meeting and Exposition 2018)
Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: A retrospective analysis.
(60th ASH Annual Meeting and Exposition 2018)
CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia: Results by multivariate analyses in the JALSG-APL204 study.
(60th ASH Annual Meeting and Exposition 2018)